SGNTUC-024 (HER2+ Gastrointestinal Cancers)
What is the Purpose of this Study?
If you choose to join this study, you will:
- Take the study drug, tucatinib, by mouth twice a day
- Get trastuzumab every 2 or 3 weeks
- Get chemotherapy and/or pembrolizumab every 2 or 3 weeks
- Give blood and urine samples
- Have regular CT or MRI scans
- Take the study drug, tucatinib, by mouth twice a day
- Get trastuzumab every 2 or 3 weeks
- Get chemotherapy and/or pembrolizumab every 2 or 3 weeks
- Give blood and urine samples
- Have regular CT or MRI scans
What is the Condition Being Studied?
HER2+ Gastrointestinal Cancer
Who Can Participate in this Study?
Adults with HER2+ cancer and one of the following tumor types:
-Colorectal carcinoma (cancer of the colon or rectum)
-Gastric adenocarcinoma (a type of stomach cancer)
-Esophageal adenocarcinoma (a type of cancer in the esophagus)
-Gastroesophageal junction adenocarcinoma (a type of cancer that occurs where the esophagus meets the stomach)
-Cholangiocarcinoma (cancer of the bile ducts)
-Gallbladder carcinoma (cancer of the gallbladder)
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to see if the study drug, tucatinib, is safe and effective to use with trastuzumab plus oxaliplatin-based chemotherapy and/or pembrolizumab. We also want to find the best dose of tucatinib to use to shrink the cancer.
Study Details
Full Title
[SGNTUC-024] A phase 1b/2 dose escalation and expansion study of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy or pembrolizumab-containing combinations for HER2+ gastrointestinal cancers
Principal Investigator
Protocol Number
IRB:
PRO00105789
NCT:
NCT04430738
ClinicalTrials.gov
View on ClinicalTrials.gov